MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461603 | Name: Mepitiostane

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mepitiostane is an epitiosteroid having anti-estrogenic and weak androgenic anabolic activities.

Chemical Structure

Mepitiostane
Mepitiostane
CAS#21362-69-6

Theoretical Analysis

MedKoo Cat#: 461603

Name: Mepitiostane

CAS#: 21362-69-6

Chemical Formula: C25H40O2S

Exact Mass: 404.2749

Molecular Weight: 404.65

Elemental Analysis: C, 74.21; H, 9.96; O, 7.91; S, 7.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mepitiostane; Mepitiostano; Mepitiostanum; S 10364; S-10364; S10364;
IUPAC/Chemical Name
(1S,3aS,3bR,5aS,6aS,7aR,8aS,8bS,10aS)-1-((1-methoxycyclopentyl)oxy)-8a,10a-dimethylhexadecahydro-1H-cyclopenta[7,8]phenanthro[2,3-b]thiirene
InChi Key
IVDYZAAPOLNZKG-KWHRADDSSA-N
InChi Code
InChI=1S/C25H40O2S/c1-23-13-10-19-17(7-6-16-14-20-21(28-20)15-24(16,19)2)18(23)8-9-22(23)27-25(26-3)11-4-5-12-25/h16-22H,4-15H2,1-3H3/t16-,17-,18-,19-,20-,21+,22-,23-,24-/m0/s1
SMILES Code
C[C@@]12[C@@H](OC3(OC)CCCC3)CC[C@@]1([H])[C@]4([H])CC[C@@]5([H])C[C@H]6[C@H](S6)C[C@]5(C)[C@@]4([H])CC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 404.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Okano M, Sato M, Kojima A, Kageyama S. Determination of mepitiostane metabolites in human urine by liquid chromatography/tandem mass spectrometry for sports drug testing. J Pharm Biomed Anal. 2015 Nov 10;115:236-44. doi: 10.1016/j.jpba.2015.07.016. Epub 2015 Jul 23. PubMed PMID: 26247800. 2: Miyai M, Takenaka K, Hayashi K, Kato M, Uematsu K, Murai H. [Effect of an oral anti-estrogen agent (mepitiostane) on the regression of intracranial meningiomas in the elderly]. Brain Nerve. 2014 Aug;66(8):995-1000. Japanese. PubMed PMID: 25082321. 3: Ichihashi T, Takagishi Y, Yamada H. Factors determining the intrinsic lymphatic partition rate of epitiostanol and mepitiostane. Pharm Res. 1992 Dec;9(12):1617-21. PubMed PMID: 1488406. 4: Ichihashi T, Kinoshita H, Takagishi Y, Yamada H. Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats. J Pharm Pharmacol. 1992 Jul;44(7):560-4. PubMed PMID: 1357134. 5: Nomura Y, Yamagata J, Takenaka K, Kanda K. Adjuvant endocrine therapy for operable breast cancer using the antiestrogen mepitiostane: a preliminary report. Gan. 1980 Aug;71(4):548-56. PubMed PMID: 6893588. 6: Maeda Y, Nakanishi T, Ozawa K, Kijima Y, Nakayama I, Shoji T, Sasaoka T. Anabolic steroid-associated hypogonadism in male hemodialysis patients. Clin Nephrol. 1989 Oct;32(4):198-201. PubMed PMID: 2805460. 7: Ichihashi T, Kinoshita H, Takagishi Y, Yamada H. Effect of bile on absorption of mepitiostane by the lymphatic system in rats. J Pharm Pharmacol. 1992 Jul;44(7):565-9. PubMed PMID: 1357135. 8: Okuno Y, Nakabou Y, Suzuki S, Ichiba S, Sugiyama H, Takahashi T, Imura H, Nakamura K, Ito M. [Complete remission by mepitiostane in hypoplastic leukemia]. Rinsho Ketsueki. 1989 Aug;30(8):1280-3. Review. Japanese. PubMed PMID: 2689684. 9: Ichihashi T, Kinoshita H, Yamada H. Absorption and disposition of epithiosteroids in rats (2): Avoidance of first-pass metabolism of mepitiostane by lymphatic absorption. Xenobiotica. 1991 Jul;21(7):873-80. PubMed PMID: 1776263. 10: Matsuzawa A, Yamamoto T. Antitumor effect of two oral steroids, mepitiostane and fluoxymesterone, on a pregnancy-dependent mouse mammary tumor (TPDMT-4). Cancer Res. 1977 Dec;37(12):4408-15. PubMed PMID: 922732. 11: Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, Masuo O, Naito Y. Regression of a presumed meningioma with the antiestrogen agent mepitiostane. Case report. J Neurosurg. 2000 Jul;93(1):132-5. PubMed PMID: 10883917. 12: Takatani O, Kumaoka S. Inhibitory effect of mepitiostane on the growth of mammary tumor of a rat. Gan. 1977 Jun;68(3):337-41. PubMed PMID: 913955. 13: Watanabe Y, Okura T, Kinoshita Y, Tamaki S, Sakamoto N, Kawahara H. [The effect of mepitiostane on the treatment of anemia in hemodialyzed patients]. Nihon Jinzo Gakkai Shi. 1982 Jun;24(6):655-63. Japanese. PubMed PMID: 7176177. 14: Izuo M, Yoshida M, Tominaga T, Abe O, Enomoto K, Nomura Y, Kubo K, Takatani O. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer. Cancer. 1985 Dec 1;56(11):2576-9. PubMed PMID: 2932213. 15: Ichihashi T, Kinoshita H, Takagishi Y, Yamada H. Intrinsic lymphatic partition rate of mepitiostane, epitiostanol, and oleic acid absorbed from rat intestine. Pharm Res. 1991 Oct;8(10):1302-6. PubMed PMID: 1796049. 16: Inoue K, Okazaki K, Morimoto T, Hayashi M, Uyama S, Sonoo H, Koshiba Y, Takihara T, Nomura Y, Yamagata J, Kondo H, Kanda K, Takenaka K. Therapeutic value of mepitiostane in the treatment of advanced breast cancer. Cancer Treat Rep. 1978 May;62(5):743-5. PubMed PMID: 657160. 17: Toyama K, Kaneko J, Suzuki H, Negishi M, Nakada I, Tobita K, Katayama T. [Treatment of aplastic anemia with mepitiostane (author's transl)]. Rinsho Ketsueki. 1979 Feb;20(2):121-7. Japanese. PubMed PMID: 439410. 18: Yamamoto T, Soejima K, Yokozeki H, Koyano T, Katayama I, Nishioka K. Unusual annular erythema associated with myelodysplastic syndrome. Dermatology. 2001;202(1):70-2. PubMed PMID: 11244236. 19: Nomura Y, Yamagata J, Kondo H, Takenaka K. Endocrine adjuvant therapy with the antiestrogen, mepitiostane, inoperable breast cancer patients on the basis of estrogen receptor assay. Gan. 1978 Apr;69(2):281-2. PubMed PMID: 680466. 20: Muraoka Y, Yahara I, Nara H, Watanabe H. Steroid-induced concentric membrane whorls in dog liver. Experientia. 1981 Apr 15;37(4):389-90. PubMed PMID: 7238820.